ImmunityBio (IBRX) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of ImmunityBio (NASDAQ: IBRX) in the last few weeks:

• 3/17/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
• 3/12/2026 – ImmunityBio is now covered by BTIG Research. They set a “buy” rating and a $13.00 price target on the stock.
• 3/11/2026 – ImmunityBio was upgraded by BTIG Research to “strong-buy”.
• 3/9/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
• 3/4/2026 – ImmunityBio had its “overweight” rating reaffirmed by Piper Sandler. They now have a $12.00 price target on the stock, up from $7.00.
• 2/23/2026 – ImmunityBio had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc..
• 2/23/2026 – ImmunityBio had its price target raised by HC Wainwright from $10.00 to $15.00. They now have a “buy” rating on the stock.
• 2/23/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $23.00 price target on the stock.
• 2/17/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.
• 1/26/2026 – ImmunityBio had its price target raised by HC Wainwright from $8.00 to $10.00. They now have a “buy” rating on the stock.
• 1/22/2026 – ImmunityBio had its price target raised by BTIG Research from $6.00 to $9.00. They now have a “buy” rating on the stock.
• 1/20/2026 – ImmunityBio had its price target raised by Piper Sandler from $5.00 to $7.00. They now have an “overweight” rating on the stock.
• 1/20/2026 – ImmunityBio had its “buy” rating reaffirmed by D. Boral Capital. They now have a $24.00 price target on the stock.

Insiders Place Their Bets

In other news, Director Christobel Selecky sold 25,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barry J. Simon sold 75,000 shares of the company’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the completion of the sale, the director directly owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. The trade was a 2.56% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 501,967 shares of company stock worth $4,466,412 in the last quarter. Corporate insiders own 69.48% of the company’s stock.

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.